

# BritMODIS 2020

31st January 2020

Birmingham Conference and Events Centre

The BGS MD SIG and PDNSA are pleased to announce details for the forthcoming BritMODIS conference for Neurologists, Geriatricians, Therapists and PD Nurse Specialists. The British Movement Disorders Group (BritMODIS) Conference will provide a forum for education in movement disorders and is organized by the British Geriatrics Society Movement Disorders Section and Parkinson's Disease Nurse Specialist Association.

## Meeting aims

- Further attendee's overall knowledge and understanding of current research and practice in healthcare of older people with movement disorders
- Improve attendee's skills in the treatment and care of older people with movement disorders
- Inspire attendees to achieve personal excellence in healthcare of older people
- Take away new activities and ideas to progress their workplace's services and improve coordination amongst healthcare professionals

## Who should attend

The meeting will be of benefit to all healthcare professionals involved with movement disorders, geriatric medicine and care of older people:

- Consultants in neurology and geriatric medicine
- General practitioners and pharmacists
- Junior doctors training in neurology and geriatric medicine
- Nurses, Nurse Consultants and Advanced Nurse Practitioners
- Occupational therapists
- Physiotherapists
- Researchers

## Partners



## In association with



## Sponsors

The British Geriatrics Society acknowledges with grateful thanks, the support given through sponsorship from:



This meeting has been applied for CPD accreditation from the Royal College of Physicians (RCP).

Register online at [www.bgs.org.uk/events](http://www.bgs.org.uk/events)

Follow us on @GeriSoc #BGSCConf

08.50 **Registration**

## Session 1

Chair: Dr Emily Henderson

**09.20 Chair's introduction**

**09.25 Palliative care in Parkinson's**

Dr Ed Richfield, Consultant geriatrician, North Bristol NHS Trust

09.20

11.00

**10.00 Drug repurposing in Parkinson's disease: progress, challenges and the future**

Dr Kelli Torsney, Academic geriatrician, Addenbrookes Hospital

**10.25 Driving in Parkinson's disease**

Dr Katie Lloyd, Academic foundation year 2 doctor, North Bristol NHS Trust and University of Bristol

11.00 **Refreshments and posters**

## Session 2

Chair: Dr Veronica Lyell

**11.30 Mortality and institutionalisation after PEG in parkinsonian conditions**

Ms Lisa Brown, Parkinson's disease nurse specialist, University Hospitals of Derby and Burton

11.30

13.00

**12.00 "My life my wishes" - advanced care planning in Parkinson's disease**

Ms Jane Price, Parkinson's nurse, Powys Teaching Health Board

**12.30 Evolution of nurse education programmes in Sub Saharan Africa**

Ms Louise Ebenezer, Parkinson's disease nurse specialist, Cwm Taf Morgannwg University Health Board

13.00 **Lunch and poster exhibition**

Poster prizes announced by Dr Victoria Haunton

13.30

14.15

**Maximising the efficacy of L-dopa: a critical role for enzyme inhibitors**

Sponsored symposium by Bial

Prof Peter Jenner, Emeritus professor of pharmacology, King's College London



## Session 3

Chairs: Dr Fionnuala Johnston and Ms Clare Johnson

**14.15 Optimisation of medicine in Parkinson's disease**

Dr Sandy Thomson, Consultant geriatrician, Salford Royal Hospital and Mr Kevin Johnson, Senior clinical pharmacist, Salford Royal Hospital

14.15

15.30

**15.00 Exercise in Parkinson's; what's the latest evidence and how to motivate patients**

Ms Fiona Lindop, Specialist physiotherapist, London Road Community Hospital

15.30 **Refreshments and posters**

## Session 4 - Excellence Network progress and plans

Chair: Dr Rob Skelly

**15.45 2019 UK Parkinson's Audit - the findings**

Dr Anne-Louise Cunnington, Consultant, Glasgow Royal Infirmary

**16.00 Building on, and working with, the Excellence Network to deliver the right care, support and opportunities to people affected**

Ms Katherine Crawford, Director of Services, Parkinson's UK

15.45

17.00

**16.20 Transforming services together: an introduction to the new Parkinson's UK strategy for 2020-2024**

Mr Steve Ford, Chief executive, Parkinson's UK

**16.40 Quality improvement: effective action planning to use UK Parkinson's audit data to create positive outcomes**

Dr Iain Wilkinson, Consultant orthogeriatrician, Surrey and Sussex Healthcare NHS Trust

17.00 **Close of meeting**

## Bial sponsored symposium



### Prof Peter Jenner

Professor Peter Jenner is a world-renowned specialist in preclinical aspects of Parkinson's and other neurodegenerative diseases. He has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Following 14 years as Head of Pharmacology, Professor Jenner is now the Emeritus Professor of Pharmacology at King's College London, and a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and King's College London. He has published more than 700 peer reviewed papers along with many chapters and monographs.


*Objectives of the symposium:*

#### Maximising the efficacy of L-dopa: a critical role for enzyme inhibitors

- To explain how difficult it is for L-dopa to reach the brain
- To explain how inhibiting L-dopa/dopamine metabolism has been key to L-dopa's success
- To look at how enzyme inhibitors act to protect L-dopa/dopamine in the periphery and brain
- To question how we use enzyme inhibitors in clinical practice

## Floor plan

### 2nd Floor



### 1st Floor




#### 1st Floor Key

 Connect 4 - Cloakroom

#### 2nd Floor Key

 Mercian 1 - Main meeting room

 Mercian 2 - Exhibition space

 Mercian foyer - Family-friendly area

 Toilets

 Lifts

 Stairs

## Ms Lisa Brown

I have worked as Parkinson's Disease Nurse Specialist at University Hospitals of Derby and Burton since 2005, working across Neurology and Medicine for the Elderly running nurse led clinics, working in a Multidisciplinary Parkinson's clinic, providing a home visit and telephone advice service and supporting Parkinson's patients admitted to hospital. I am an Independent Nurse Prescriber, hold a BSc(Hons) Degree in Specialist Nursing Practice and have developed the scope of my practice to include botulinum toxin injections to treat Cervical Dystonia and Sialorrhoea. I sit on the UK Parkinson's Audit Governance Board and am a committee member of the Parkinson's Disease Nurse Specialist Association.

### *Speaker abstract*

PEG feeding provides a means of getting food, liquid and medication into the stomach in people with Parkinsonian conditions and dysphagia. Information of survival and complications post PEG might inform feeding decisions. We audited 83 patients from 2 institutions over more than a decade. We found 30 day mortality of 6%, median survival of 387 days and rate of institutionalisation of 32%.

## Ms Katherine Crawford

Katherine joined Parkinson's UK in 2004 and have worked in a variety of roles, from direct support for people living with Parkinson's, to leading and managing the charity's work in Scotland. She is now overseeing Parkinson's UK direct support services and local networks across the UK. She has a varied career prior to joining Parkinson's UK, having practised as a solicitor, owned and run an outdoor events and tourism company, and worked in adult education. She aims to bring the range of skills she's developed over the years to help ensure Parkinson's local services are the best they can be

## Dr Anne-Louise Cunnington

Anne-Louise is a Consultant Geriatrician with an interest in Movement Disorders at Glasgow Royal Infirmary. She is an Honorary Clinical Senior Lecturer at Glasgow University. She has been involved in the Parkinson's National Audit since its inception in 2008, and has been the Clinical Audit Lead since January 2014. She represents audit and clinical effectiveness on the BGS Movement Disorder Subgroup and is the West of Scotland Parkinson's Excellence Network regional lead. She is the chair for the Regional Ethics committee 3 in the West of Scotland. She has published over 40 papers.

### *Speaker abstract*

The 2019 UK Parkinson's Audit provides the largest ever dataset about the quality of evidence based care delivered to people with Parkinson's across the UK. Evidence of good practice as well as areas for improvement will be highlighted from the separate audit components: from doctors and nursing staff, occupational therapists, physiotherapists and speech and language therapists as well as from the Patient Reported Experience Measure (PREM). Key messages will be drawn together and discussed.

## Ms Louise Ebenezer

Louise qualified as a Registered Nurse in 1988, working in acute medicine and then a Ward Manager in Care of the Elderly medicine. She has been a Clinical Nurse Specialist for Parkinson's disease since 2003. Louise gained a Masters degree in 2004 in Care of the Older Person, she is an independent prescriber. Louise manages a case load of over 500 patients with Parkinson's disease and related disorders, from diagnosis through to end of life. She runs her own nurse-led community clinics, as well as twice weekly parallel clinics within Princess of Wales Hospital. She is an honorary lecturer in Swansea University and co-facilitates and teaches on the Parkinson's disease course – 'Nursing Management of Parkinson's disease and related disorders'. She is vice-chair of Parkinson's Disease Nurse Specialist Association (PDNSA). Louise also co-facilitates and helped set up the first Parkinson's disease nurse course in Sub Saharan Africa.

## Mr Steve Ford

Steve joined Parkinson's UK as chief executive in 2005 after a career as general manager and chief executive in the NHS. Under his leadership, the charity has made significant progress towards its vision to find a cure and

improve life for everyone affected by Parkinson's. Steve believes strongly that change is best delivered in partnership. He's bringing together everyone in the Parkinson's community to speed up research, raise standards of care and empower people affected by the condition to take more control of their lives. Putting people living with Parkinson's at the heart of the charity has created passion and urgency. Steve believes that is the key to achieving Parkinson's UK's ambitious goals.

### *Speaker abstract*

Parkinson's UK is launching our next 5 year strategy for the Parkinson's community. Over the last few years we've all made an impact. It's now time to do it Bigger, Better and Faster. I'll set out plans for the Excellence Network and some exciting new initiatives

## Mr Kevin Johnson

Senior clinical pharmacist and Lead/Directorate pharmacist at SRFT Emergency Assessment Unit/Emergency department  
Non-Medical Prescriber since 2012  
Specialist interest in Parkinson's disease  
Prescriber of growth hormones for the endocrinology dept at SRFT

### *Speaker abstract*

The aim of this talk will be to explore ways in which medication can be optimized in patients with Parkinson's disease. This will include dopaminergic medication, other pharmacological treatments used in PD, and wider prescribing issues in this patient group. The audience will be encouraged to think about ways in which they approach medicines management in patients that they see, and how this may be improved in their own localities.

## Mrs Fiona Lindop

I am a specialist physiotherapist in Parkinson's disease and related conditions, working as part of the Parkinson's Centre of Excellence multidisciplinary team in Derby. I am also the Clinical Therapy Lead for Parkinson's UK Excellence Network. I represented physiotherapy on the review body for the 2017 NICE Guideline for Parkinson's, as well as the NICE Quality Standards for Parkinson's. I sit on the steering committee and governance board for the national audit of NICE guidelines for Parkinson's.

### *Speaker abstract*

This presentation will cover the latest evidence for the benefits of exercise in Parkinson's, and what types of exercise are indicated. It will also address the barriers to exercise and what we can do to motivate people with Parkinson's to increase their physical activity and exercise. It will include information about initiatives and programmes designed to offer opportunities for people with Parkinson's to participate in exercise.

## Dr Katie Lloyd

Katie Lloyd graduated from the University of Bristol in 2018 and is now working as an academic F2 doctor in Bristol. She is an aspiring academic neurologist. Her research interests are in movement disorders and cognition.

### *Speaker abstract*

**Background**  
Patients with Parkinson's disease (PD) who drive, may need to undergo specialist driving assessment. Driving is important in maintaining patient's independence but there is no consensus on what predicts ability to safely drive or a validated battery of tests for use in driving assessments of PD patients.

### **Objectives**

To describe the characteristics of PD patients assessed at a Driving Mobility Centre and investigate factors that predicted driving assessment outcome.

### **Methods**

Retrospective cohort study of PD patients assessed between 2012-2016. Descriptive analyses and logistic models to determine factors predicting a negative outcome.

## Results

There were 86 assessments of PD patients. The mean age was 70 years ( $\bar{A} \pm 9.2$ ), 86% were men, median disease duration 7 years (Inter Quartile Range 5–12.5 years) and 59% were referred by the DVLA. 62% had a negative Not Drive outcome. The best predictors were the Rookwood Driving Battery (RDB) (Odds ratio [OR] 1.45, 95% confidence interval [CI] 1.17, 1.80,  $p=0.001$ ), depth of vision deficit (OR 4.95, 95% CI 1.62, 15.1,  $p=0.005$ ) and usual driving frequency (International/National OR 1, Regional OR 7.33, 95% CI 1.47, 36.7,  $p=0.015$ , Local OR 4.67, 95% CI 1.39, 15.7,  $p=0.013$ ) with age, duration license held and reaction time being weaker predictors in univariable analysis. The RDB score was the best predictor of assessment failure, conditional on other variables in a backward stepwise model (OR 1.29, 95% CI 1.05, 1.60,  $p=0.015$ ).

## Conclusions

This is the first study to describe PD patients undergoing driving assessments in the UK. We found current tests of ability are predictive of outcome. Future studies are required to determine which early disease features predict driving ability and develop simpler valid screening tests. “

## Ms Jane Price

Jane Price is a Parkinson's Disease Nurse Advanced Practitioner in Powys. She is based in Bronllys Hospital, working across both the primary and secondary care setting. Qualified in 1986, she has been a Parkinson's nurse since 2003 undertaking Independent prescribing, a Post Graduate Certificate in Education and MSc in Care of the Older Person. She is the current Chair of the Parkinson's Disease Nurse Specialist Association (PDNSA), which works in partnership with Parkinson's UK and the Parkinson's Excellence Network to promote and establish high quality exemplary practice and services. She is a committee member of the Parkinson's Information Network (PINK), committed to providing education and self-development for nurses to benefit their own services and ultimately the lives of people living with Parkinson's.

### *Speaker abstract*

The aim of this session is to increase awareness of the importance of starting conversations around advanced care planning (ACP) for people living with Parkinson's disease. It is acknowledged that there can be real and perceived barriers that impact on when and how these conversations take place. This session aims to identify ways that the Parkinson's nurse can introduce and promote ongoing ACP conversations to better support all involved in the care and management of people living with PD

## Dr Ed Richfield

Ed Richfield is a consultant in Elderly medicine with a sub-specialty of movement disorders. He was recently appointed at North Bristol Trust, having previously worked and trained in Yorkshire and his PhD, from Hull York Medical School, is titled “Palliative care in Parkinson's disease: developing a needs assessment tool”. He has been involved in the Neurology Academy as a delegate and faculty member since 2014. He is a member of the Movement disorders Society (MDS) taskforce exploring palliative care in Parkinson's disease.

## Dr Sandy Thomson

Sandy Thomson is a consultant physician and Geriatrician at Salford Royal Hospital. He looks after a predominately older, frailer group of adults living with Parkinson's disease in both in-patient and out-patient settings.

In recent years he has worked with colleagues to develop front door services for Parkinson's patients admitted to hospital, creating pathways and care bundles to promote safety in this vulnerable patient group.

He has interests in Medical Education, is an established faculty member for the Parkinson's Masterclass with the Neurology Academy, and is a self-confessed delirium obsessive.

### *Speaker abstract*

The aim of this talk will be to explore ways in which medication can be optimized in patients with Parkinson's disease. This will include dopaminergic medication, other pharmacological treatments used in PD, and wider prescribing issues in this patient group. The audience will be encouraged to think about ways in which they approach medicines management in patients that they see, and how this may be improved in their own localities.

## Dr Kelli Torsney

Dr Kelli Torsney is currently undertaking a PhD in Clinical Neurosciences at Cambridge University focusing on models of ageing and translation research in Parkinson's disease. Her research interests include non-motor manifestations of Parkinson's disease and representative models for ageing research. Kelli is also actively involved in the British Geriatrics Society and has recently been appointed as the new junior editorial fellow for Age and Ageing.

### *Speaker abstract*

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. Despite this there are still no disease modifying treatments to slow or halt disease progression. Given the slowly progressive nature of Parkinson's disease and the number of failures of various novel interventions in disease modifying clinical trials, attention is turning to utilising existing drugs approved for other conditions as novel treatments for Parkinson's disease. This approach is known as drug repurposing. Drug repurposing has become a popular strategy in recent years. It is both efficient and economical with fewer risks. This talk will cover the progress and future outlook of drug repurposing in Parkinson's disease as well as the challenges we face.

## Dr Iain Wilkinson

Dr Iain Wilkinson is a Consultant Geriatrician interested in Orthogeriatrics, parkinson's disease and quality improvement. He is TPD for Kent, Surrey and Sussex and presenter of MDTea podcast